NICE Overturns Bavencio Rejection After Merck/Pfizer Win Appeal On English Funding
Over 800 People With Urothelial Cancer Set To Benefit From Bavencio
As well as now backing the reimbursement of Bavencio for urothelial cancer, the health technology assessment institute has recommended Koselugo, for neurofibromatosis type 1, and Evenity, the osteoporosis drug that will now target over 20,000 people in England and Wales. On the other hand, Piqray has for now been turned down for advanced breast cancer.
You may also be interested in...
Health technology assessment body NICE has reversed its previous rejections of Novartis’s Piqray and Gilead’s Trodelvy, both for treating advanced breast cancer. Meanwhile, there are calls to speed up reimbursement decisions for breast cancer drugs.
In a draft decision NICE, the health technology appraisal body for England and Wales, has declined to recommend Gilead’s Trodelvy for triple negative breast cancer patients.
Bavencio, Taltz, Cosentyx, and Opdivo plus Yervoy were this week also the subject of final recommendations from the health technology assessment body, NICE, on whether or not they should be used on the National Health Service for certain indications.